FRANKFURT, Germany (Reuters) — Bayer investor Jeff Ubben has contacted fellow shareholders in the German company, investors and sources familiar with the matter said, in an apparent attempt to rally support for big changes at the drugs-to-pesticides company.
The campaign increases the pressure on non-executive chair Norbert Winkeljohann, who has faced calls from large shareholders for the swift replacement of chief executive officer Werner Baumann, who engineered Bayer’s troubled Monsanto takeover.
The approaches come after Ubben’s activist investment fund Inclusive Capital Partners said last month it had bought a 0.83 percent stake in Bayer.
Read Also
Head of Bayer Canada bullish on biofuel sector
Antoine Bernet, country head of Canada for Bayer Crop Science, believes that biofuels represent a massive opportunity for oilseed growers in Canada. One of those oilseed crops is camelina, as Bayer recently acquired a camelina company from Saskatoon
Ubben said at the time he would prefer an external candidate to replace Baumann and that while a break-up of the company may not be necessary, it needs to be considered.
David Herro, deputy chair of Harris Associates, said in emailed comments that Ubben had contacted him to discuss Bayer. He did not provide further details.
Ubben has also been in touch with a portfolio manager at a large German mutual funds firm, and proposed a meeting, according to a person familiar with the matter.
Another source said Ubben had reached out to many institutional Bayer investors to get support for a campaign to quickly replace Baumann with a candidate from outside the company to revive the sagging share price.
The investors declined to be identified due to the sensitivity of the matter.
Ubben did not respond to requests for comment.
A spokesperson said Bayer was always open to a constructive dialogue with shareholders and declined to comment further.
Two large German mutual companies and major Bayer shareholders Union Investment and Deka have also said they would like a swift CEO changeover at the company, whose business spans drugs, consumer health-care products, seeds and pesticides.
Investors who have publicly called for a swift CEO change hold at least a combined 6.7 percent in Bayer, according to Refinitiv data.
Activist investor Bluebell Capital Partners, which has built an undisclosed stake, is looking for something similar. It also wants a break-up of the company.
It’s unclear if there is consensus on the strategic changes that shareholders want the future leadership to pursue.
Speaking on condition of anonymity, one fund manager said a break-up of Bayer must not be rushed and may come in gradual moves.
Harris Associates’s Herro said he preferred an external CEO appointment soon but added there was “nothing specific” when asked about his demands regarding strategy and group structure.
Any attempts by shareholders to co-ordinate how they exert influence over a company is a balancing act because shareholders who are found to act in concert and hold a combined 30 percent voting stake must make a takeover offer to the remaining shareholders under German law.
Other obligations that come with acting in concert include publication of the size of jointly held stakes, which financial and activist investors typically seek to avoid.
The annual shareholder meeting scheduled for April 28 will be an opportunity for investors to express their views.
Despite recent improvements in the company’s agriculture business and drug development prospects, Bayer shares have been weighed down by litigation related to a product it acquired through its 2018 takeover of Monsanto.
A stalwart of German industry with a nearly 160-year history, Bayer has lost more than 40 percent of its market value since buying Monsanto.
Shareholders have also cited a lack of market confidence in top management as a burden on shares.
Baumann, who engineered the Monsanto deal with the backing of then chair Werner Wenning, was given a new contract in 2020 that runs until 2024 and said at the time he would leave the company when that expires.
